Works matching Reverse transcriptase

Results: 5000
    1

    Expression of the Reverse Transcriptase Domain of Telomerase Reverse Transcriptase Induces Lytic Cellular Response in DNA-Immunized Mice and Limits Tumorigenic and Metastatic Potential of Murine Adenocarcinoma 4T1 Cells.

    Published in:
    Vaccines, 2020, v. 8, n. 2, p. 318, doi. 10.3390/vaccines8020318
    By:
    • Jansons, Juris;
    • Bayurova, Ekaterina;
    • Skrastina, Dace;
    • Kurlanda, Alisa;
    • Fridrihsone, Ilze;
    • Kostyushev, Dmitry;
    • Kostyusheva, Anastasia;
    • Artyuhov, Alexander;
    • Dashinimaev, Erdem;
    • Avdoshina, Darya;
    • Kondrashova, Alla;
    • Valuev-Elliston, Vladimir;
    • Latyshev, Oleg;
    • Eliseeva, Olesja;
    • Petkov, Stefan;
    • Abakumov, Maxim;
    • Hippe, Laura;
    • Kholodnyuk, Irina;
    • Starodubova, Elizaveta;
    • Gorodnicheva, Tatiana
    Publication type:
    Article
    2
    3

    Designing one-step reverse transcriptase loop-mediated isothermal amplification for serotype O foot-and-mouth disease virus detection during the 2022 outbreak in East Java, Indonesia.

    Published in:
    Veterinary World, 2023, v. 16, n. 9, p. 1889, doi. 10.14202/vetworld.2023.1889-1896
    By:
    • Aksono, Eduardus Bimo;
    • Lamid, Mirni;
    • Rimayanti, Rimayanti;
    • Hamid, Iwan Sahrial;
    • Effendi, Mustofa Helmi;
    • Rantam, Fedik Abdul;
    • Widjiati, Widjiati;
    • Mufasirin, Mufasirin;
    • Puspitasari, Heni;
    • Fitria, Munawaroh;
    • Fajar, Nur Syamsiatul;
    • Suwanti, Lucia Tri;
    • Nusdianto, Nusdianto;
    • Zaidan, Andi Hamim;
    • Yuta Kanai;
    • Sucipto, Teguh Hari
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

    Published in:
    HIV Medicine, 2008, v. 9, n. 10, p. 883, doi. 10.1111/j.1468-1293.2008.00644.x
    By:
    • Ruxrungtham, K.;
    • Pedro, R. J.;
    • Latiff, G. H.;
    • Conradie, F.;
    • Domingo, P.;
    • Lupo, S.;
    • Pumpradit, W.;
    • Vingerhoets, J. H.;
    • Peeters, M.;
    • Peeters, I.;
    • Kakuda, T. N.;
    • De Smedt, G.;
    • Woodfall, B.
    Publication type:
    Article
    13
    14

    High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.

    Published in:
    Frontiers in Microbiology, 2022, v. 13, p. 1, doi. 10.3389/fmicb.2022.973771
    By:
    • Parbie, Prince Kofi;
    • Abana, Christopher Zaab-Yen;
    • Kushitor, Dennis;
    • Asigbee, Theodore Worlanyo;
    • Ntim, Nana Afia Asante;
    • Addo-Tetebo, Gifty;
    • Ansong, Maclean Richard Darko;
    • Ofori, Sampson Badu;
    • Taketoshi Mizutani;
    • Runtuwene, Lucky Ronald;
    • Masako Nishizawa;
    • Koichi Ishikawa;
    • Hiroshi Kiyono;
    • Ampofo, William Kwabena;
    • Tetsuro Matano;
    • Bonney, Evelyn Yayra;
    • Tadashi Kikuchi
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach.

    Published in:
    Molecules, 2023, v. 28, n. 7, p. 3103, doi. 10.3390/molecules28073103
    By:
    • Mansouri, Mahta;
    • Rumrill, Shawn;
    • Dawson, Shane;
    • Johnson, Adam;
    • Pinson, Jo-Anne;
    • Gunzburg, Menachem J.;
    • Latham, Catherine F.;
    • Barlow, Nicholas;
    • Mbogo, George W.;
    • Ellenberg, Paula;
    • Headey, Stephen J.;
    • Sluis-Cremer, Nicolas;
    • Tyssen, David;
    • Bauman, Joseph D.;
    • Ruiz, Francesc X.;
    • Arnold, Eddy;
    • Chalmers, David K.;
    • Tachedjian, Gilda
    Publication type:
    Article
    42
    43
    44

    Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

    Published in:
    HIV Medicine, 2013, v. 14, n. 9, p. 571, doi. 10.1111/hiv.12044
    By:
    • Santoro, MM;
    • Sabin, C;
    • Forbici, F;
    • Bansi, L;
    • Dunn, D;
    • Fearnhill, E;
    • Boumis, E;
    • Nicastri, E;
    • Antinori, A;
    • Palamara, G;
    • Callegaro, A;
    • Francisci, D;
    • Zoncada, A;
    • Maggiolo, F;
    • Zazzi, M;
    • Perno, CF;
    • Ceccherini‐Silberstein, F;
    • Mussini, C
    Publication type:
    Article
    45
    46
    47
    48
    49
    50